The chickenpox vaccine market size has grown strongly in recent years. It will grow from $3.57 billion in 2024 to $3.8 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to vaccine development, regulatory approvals, disease incidence, vaccination policies, public health initiatives.
The chickenpox vaccine market size is expected to see strong growth in the next few years. It will grow to $4.93 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to public perception and trust, pandemic preparedness, research and development, emerging market demand, healthcare infrastructure development. Major trends in the forecast period include vaccine education campaigns, adverse event monitoring, vaccine pricing strategies, advanced innovation, use of AI.
The increasing prevalence of chickenpox is anticipated to drive growth in the chickenpox vaccine market. Chickenpox is a highly contagious disease caused by the varicella-zoster virus (VZV), characterized by a fluid-filled rash that is intensely itchy. The rising number of chickenpox cases necessitates more varicella vaccinations, boosting demand for chickenpox vaccines. For instance, in October 2023, a report by the National Library of Medicine (NLM), a US-based biomedical library, shared findings from a study on GP consultations for chickenpox from September 2016 to December 2022, revealing an average weekly rate of 3.4 per 100,000 people in England, with consistent peaks between weeks 13 and 15 each year. However, during the COVID-19 pandemic, typical seasonal peaks were absent, likely due to social distancing and lockdown measures. In 2022, consultation rates increased among children under 1 year old compared to pre-pandemic years, suggesting altered transmission patterns. Therefore, the rising prevalence of chickenpox is driving the demand for chickenpox vaccines.
The rising awareness of vaccination benefits is expected to propel the chickenpox vaccine market. Vaccination involves introducing weakened or inactive forms of a virus or bacteria into the body to build immunity. Increased awareness about the chickenpox vaccine promotes higher vaccination rates, which help reduce disease incidence. For example, in November 2022, the World Health Organization (WHO) released its Global Vaccine Market Report 2022, highlighting that limited vaccine supply and unequal distribution contribute to global health disparities. The report noted that approximately 16 billion vaccine doses, valued at $141 billion, were supplied globally, with COVID-19 vaccines being a significant driver of this increase. Consequently, rising awareness of vaccination benefits is bolstering the chickenpox vaccine market.
Novel drug developments are a key trend gaining traction in the chickenpox vaccine market. Leading companies in this market are focusing on developing new drugs with enhanced efficacy and innovative derivatives to maintain their market position. For example, in November 2022, Sinovac Biotech Ltd., a China-based vaccine research, development, and manufacturing company, announced that the World Health Organization (WHO) granted prequalification for its live attenuated chickenpox (varicella) vaccine, marking it as the world's first varicella vaccine to receive this designation. The varicella vaccine, derived from the Oka strain, is manufactured in SINOVAC’s exclusive Human Diploid Cell (SV-1 strain) through virus cultivation, stabilizer addition, and freeze-drying. A phase III efficacy study showed a seroconversion rate of 97.1% in children aged 1 to 12 years, the vaccine's efficacy against varicella and breakthrough varicella was 87.1% and 89.2%, respectively. The vaccine provides complete protection against both mild and severe cases.
Leading companies in the chickenpox vaccine market are prioritizing research and development (R&D) investments to introduce advanced vaccine formulations. R&D investments refer to funds allocated by organizations, including companies, governments, and research institutions, for innovation and advancement in specific fields. For example, in February 2022, as reported by GOV.UK, the UK government committed £10 million to vaccine research targeting epidemic prevention in developing countries. The UK Vaccine Network selected 22 research projects to address viruses such as Ebola, Lassa fever, and Zika.
In July 2022, GC LabCell, a prominent biotechnology company based in South Korea, finalized a definitive merger agreement with GC Cell Corporation, also based in South Korea, which specializes in the production of chickenpox vaccine. This strategic merger unites two distinguished biopharmaceutical entities from South Korea, each with its unique strengths and portfolios. The combined entity benefits from highly complementary portfolios, bolstered by an extensive cell therapy research and development pipeline. Additionally, the merger leverages cutting-edge manufacturing capabilities, positioning the consolidated company to expedite its growth trajectory significantly. This strategic move is expected to foster accelerated growth and enhance value creation within the biopharmaceutical landscape.
Major companies operating in the chickenpox vaccine market include Merck & Co., Sanofi Pasteur, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Seqirus, Serum Institute of India Pvt. Ltd., Bharat Biotech, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Adimmune Corporation, Biological E. Limited, Walvax Biotechnology Co., Ltd., Zydus Cadila, Indian Immunologicals Ltd., Panacea Biotec Ltd., Bio Farma, PT Kalbe Farma Tbk, CanSino Biologics.
North America was the largest region in the chickenpox vaccine market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chickenpox vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chickenpox vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chickenpox vaccines stimulate the immune response, triggering antibody production against varicella-zoster viruses, preventing future infections. The virus causes highly contagious chickenpox (VZV).
The primary types of chickenpox vaccines are the monovalent varicella vaccine and the combination varicella vaccine. The monovalent varicella vaccine contains a live, weakened virus highly effective in generating antibodies, with a single dose inducing antibody formation in about 97% of school-aged recipients. These vaccines have diverse applications, including immunization against mumps, measles, rubella, varicella, herpes zoster, and chickenpox. They are utilized across various end-users such as hospitals, clinics, and other medical settings.
The chickenpox vaccine market research report is one of a series of new reports that provides chickenpox vaccine optical components market statistics, including chickenpox vaccine optical components industry global market size, regional shares, competitors with a chickenpox vaccine optical components market share, detailed chickenpox vaccine optical components market segments, market trends and opportunities, and any further data you may need to thrive in the chickenpox vaccine optical components industry. This chickenpox vaccine optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chickenpox vaccines market consists of sales of single-antigen varicella vaccines and mixed-antigen varicella vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The chickenpox vaccine market size is expected to see strong growth in the next few years. It will grow to $4.93 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to public perception and trust, pandemic preparedness, research and development, emerging market demand, healthcare infrastructure development. Major trends in the forecast period include vaccine education campaigns, adverse event monitoring, vaccine pricing strategies, advanced innovation, use of AI.
The increasing prevalence of chickenpox is anticipated to drive growth in the chickenpox vaccine market. Chickenpox is a highly contagious disease caused by the varicella-zoster virus (VZV), characterized by a fluid-filled rash that is intensely itchy. The rising number of chickenpox cases necessitates more varicella vaccinations, boosting demand for chickenpox vaccines. For instance, in October 2023, a report by the National Library of Medicine (NLM), a US-based biomedical library, shared findings from a study on GP consultations for chickenpox from September 2016 to December 2022, revealing an average weekly rate of 3.4 per 100,000 people in England, with consistent peaks between weeks 13 and 15 each year. However, during the COVID-19 pandemic, typical seasonal peaks were absent, likely due to social distancing and lockdown measures. In 2022, consultation rates increased among children under 1 year old compared to pre-pandemic years, suggesting altered transmission patterns. Therefore, the rising prevalence of chickenpox is driving the demand for chickenpox vaccines.
The rising awareness of vaccination benefits is expected to propel the chickenpox vaccine market. Vaccination involves introducing weakened or inactive forms of a virus or bacteria into the body to build immunity. Increased awareness about the chickenpox vaccine promotes higher vaccination rates, which help reduce disease incidence. For example, in November 2022, the World Health Organization (WHO) released its Global Vaccine Market Report 2022, highlighting that limited vaccine supply and unequal distribution contribute to global health disparities. The report noted that approximately 16 billion vaccine doses, valued at $141 billion, were supplied globally, with COVID-19 vaccines being a significant driver of this increase. Consequently, rising awareness of vaccination benefits is bolstering the chickenpox vaccine market.
Novel drug developments are a key trend gaining traction in the chickenpox vaccine market. Leading companies in this market are focusing on developing new drugs with enhanced efficacy and innovative derivatives to maintain their market position. For example, in November 2022, Sinovac Biotech Ltd., a China-based vaccine research, development, and manufacturing company, announced that the World Health Organization (WHO) granted prequalification for its live attenuated chickenpox (varicella) vaccine, marking it as the world's first varicella vaccine to receive this designation. The varicella vaccine, derived from the Oka strain, is manufactured in SINOVAC’s exclusive Human Diploid Cell (SV-1 strain) through virus cultivation, stabilizer addition, and freeze-drying. A phase III efficacy study showed a seroconversion rate of 97.1% in children aged 1 to 12 years, the vaccine's efficacy against varicella and breakthrough varicella was 87.1% and 89.2%, respectively. The vaccine provides complete protection against both mild and severe cases.
Leading companies in the chickenpox vaccine market are prioritizing research and development (R&D) investments to introduce advanced vaccine formulations. R&D investments refer to funds allocated by organizations, including companies, governments, and research institutions, for innovation and advancement in specific fields. For example, in February 2022, as reported by GOV.UK, the UK government committed £10 million to vaccine research targeting epidemic prevention in developing countries. The UK Vaccine Network selected 22 research projects to address viruses such as Ebola, Lassa fever, and Zika.
In July 2022, GC LabCell, a prominent biotechnology company based in South Korea, finalized a definitive merger agreement with GC Cell Corporation, also based in South Korea, which specializes in the production of chickenpox vaccine. This strategic merger unites two distinguished biopharmaceutical entities from South Korea, each with its unique strengths and portfolios. The combined entity benefits from highly complementary portfolios, bolstered by an extensive cell therapy research and development pipeline. Additionally, the merger leverages cutting-edge manufacturing capabilities, positioning the consolidated company to expedite its growth trajectory significantly. This strategic move is expected to foster accelerated growth and enhance value creation within the biopharmaceutical landscape.
Major companies operating in the chickenpox vaccine market include Merck & Co., Sanofi Pasteur, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Seqirus, Serum Institute of India Pvt. Ltd., Bharat Biotech, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Adimmune Corporation, Biological E. Limited, Walvax Biotechnology Co., Ltd., Zydus Cadila, Indian Immunologicals Ltd., Panacea Biotec Ltd., Bio Farma, PT Kalbe Farma Tbk, CanSino Biologics.
North America was the largest region in the chickenpox vaccine market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chickenpox vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chickenpox vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chickenpox vaccines stimulate the immune response, triggering antibody production against varicella-zoster viruses, preventing future infections. The virus causes highly contagious chickenpox (VZV).
The primary types of chickenpox vaccines are the monovalent varicella vaccine and the combination varicella vaccine. The monovalent varicella vaccine contains a live, weakened virus highly effective in generating antibodies, with a single dose inducing antibody formation in about 97% of school-aged recipients. These vaccines have diverse applications, including immunization against mumps, measles, rubella, varicella, herpes zoster, and chickenpox. They are utilized across various end-users such as hospitals, clinics, and other medical settings.
The chickenpox vaccine market research report is one of a series of new reports that provides chickenpox vaccine optical components market statistics, including chickenpox vaccine optical components industry global market size, regional shares, competitors with a chickenpox vaccine optical components market share, detailed chickenpox vaccine optical components market segments, market trends and opportunities, and any further data you may need to thrive in the chickenpox vaccine optical components industry. This chickenpox vaccine optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chickenpox vaccines market consists of sales of single-antigen varicella vaccines and mixed-antigen varicella vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Chickenpox Vaccine Market Characteristics3. Chickenpox Vaccine Market Trends and Strategies4. Chickenpox Vaccine Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Chickenpox Vaccine Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Chickenpox Vaccine Market34. Recent Developments in the Chickenpox Vaccine Market
5. Global Chickenpox Vaccine Growth Analysis and Strategic Analysis Framework
6. Chickenpox Vaccine Market Segmentation
7. Chickenpox Vaccine Market Regional and Country Analysis
8. Asia-Pacific Chickenpox Vaccine Market
9. China Chickenpox Vaccine Market
10. India Chickenpox Vaccine Market
11. Japan Chickenpox Vaccine Market
12. Australia Chickenpox Vaccine Market
13. Indonesia Chickenpox Vaccine Market
14. South Korea Chickenpox Vaccine Market
15. Western Europe Chickenpox Vaccine Market
16. UK Chickenpox Vaccine Market
17. Germany Chickenpox Vaccine Market
18. France Chickenpox Vaccine Market
19. Italy Chickenpox Vaccine Market
20. Spain Chickenpox Vaccine Market
21. Eastern Europe Chickenpox Vaccine Market
22. Russia Chickenpox Vaccine Market
23. North America Chickenpox Vaccine Market
24. USA Chickenpox Vaccine Market
25. Canada Chickenpox Vaccine Market
26. South America Chickenpox Vaccine Market
27. Brazil Chickenpox Vaccine Market
28. Middle East Chickenpox Vaccine Market
29. Africa Chickenpox Vaccine Market
30. Chickenpox Vaccine Market Competitive Landscape and Company Profiles
31. Chickenpox Vaccine Market Other Major and Innovative Companies
35. Chickenpox Vaccine Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Chickenpox Vaccine Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on chickenpox vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for chickenpox vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chickenpox vaccine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Vaccine: Monovalent Varicella Vaccine; Combination Varicella Vaccine2) By Application: Mumps, Measles, Rubella, and Varicella Immunization; Herpes Zoster Immunization; Chickenpox Vaccination
3) By End-Users: Hospitals; Clinics; Other End-Users
Subsegments:
1) By Monovalent Varicella Vaccine: Live Attenuated Varicella Vaccine2) By Combination Varicella Vaccine: Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine
Key Companies Mentioned: Merck & Co.; Sanofi Pasteur; Takeda Pharmaceutical Company Limited; CSL Limited; Pfizer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co.
- Sanofi Pasteur
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Pfizer Inc.
- Seqirus
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Emergent BioSolutions Inc.
- Hualan Biological Engineering Inc.
- Shenzhen Kangtai Biological Products Co.
- Ltd.
- Chongqing Zhifei Biological Products Co.
- Ltd.
- Beijing Minhai Biotechnology Co.
- Ltd.
- Adimmune Corporation
- Biological E. Limited
- Walvax Biotechnology Co.
- Ltd.
- Zydus Cadila
- Indian Immunologicals Ltd.
- Panacea Biotec Ltd.
- Bio Farma
- PT Kalbe Farma Tbk
- CanSino Biologics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.8 Billion |
| Forecasted Market Value ( USD | $ 4.93 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
